Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Iron Deficiency Injectable Market Size From 2025 to 2034?
In recent times, the market size for injectable treatments against iron deficiency has experienced robust growth. It’s projected to expand from $14.06 billion in 2024 to $15.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. The growth seen in the historical period can be linked to factors such as the high rate of treatment for iron deficiency anemia, the number of patients undergoing bariatric surgery, increasing cases in pediatric and adolescent patients, as well as in pregnancies.
The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $22.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Iron Deficiency Injectable Market?
The escalating commonality of polycystic ovary syndrome (PCOS) is predicted to drive the expansion of the iron deficiency injectables market in the future. Essentially a frequent hormone imbalance that predominates in individuals with ovaries, particularly those in their childbearing years, PCOS is known to trigger iron overload. This, in turn, leads to extensive blood loss during menses, resulting in anemia, a condition that can be treated with injectable iron-deficiency drugs. For example, the World Health Organization, a US-based health-focused organization, reported in June 2023 that globally, PCOS impacts an estimated 8-13% of women in the reproductive age group, with 70% of these cases remaining undiagnosed. Thus, the growing incidence of polycystic ovary syndrome (PCOS) is creating a positive impact on the growth of the iron deficiency injectables market.
Which Key Market Segments Comprise the Iron Deficiency Injectable Market and Drive Its Revenue Growth?
The iron deficiency injectablemarket covered in this report is segmented –
1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
2) By Branded or Generics: Branded; Generics
3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran; High Molecular Weight Iron Dextran
2) By Iron Sucrose: Venofer
3) By Ferric Carboxymaltose: Injectafer; Ferinject
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12907&type=smp
Which Areas Are Leading Regions in the Iron Deficiency Injectable Market Expansion Across the Globe?
North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Key Market Trends in theIron Deficiency Injectable Market Over the Coming Years?
Leading businesses in the iron deficiency injectables market, like INJECTAFER, are formulating new treatments to maintain their market dominance. In June 2023, the US-based healthcare firm Daiichi Sankyo Company, along with American Regent Inc., a US-based manufacturer of injectables, unveiled INJECTAFER (ferric carboxymaltose injection) targeted at iron deficiency. This was endorsed by the Food And Drug Administration (FDA), a government agency in the US. The approval marked the product as the first and only IV iron substitute therapy for adults suffering from chronic and advancing heart failure to gain FDA approval. The FDA greenlit this therapy following the evaluation of over 40 clinical trials involving more than 8,800 subjects from across the globe using INJECTAFER. This latest sanction underlines INJECTAFER’s successful and proven application for patients, encompassing both adult and pediatric patients dealing with iron-deficient anemia and heart issues.
View the full report here:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
How Is the Iron Deficiency Injectable Market Conceptually Defined?
Iron deficiency refers to a condition where the body lacks adequate iron, leading to decreased production of red blood cells and hemoglobin. Iron deficiency injectables refer to injectable medications or solutions used to treat iron deficiency. These injectable forms of iron allow for direct delivery of the iron into the bloodstream, bypassing the digestive system.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12907
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model